Calian to Aid ZYUS in Advancing Lead Drug Candidate Trial

Calian Group Ltd., a company renowned for its diverse range of products and services in healthcare, communications, learning, and cybersecurity, has been awarded a significant contract to support ZYUS Life Science's Phase 2 Clinical Trial for their Trichomylin® softgel capsules. This trial is aimed at advanced cancer patients who suffer from moderate to severe pain related to their condition.

The CRO of Calian will utilize its extensive experience in clinical trial management to facilitate the trial. The trial is designed as a double-blinded, placebo-controlled, randomized, and multiple dose escalation study. Derek Clark, President of Calian Health, expressed enthusiasm for the project, highlighting the company's commitment to improving health outcomes and exploring the potential of Trichomylin softgel capsules in chronic pain management.

The Trichomylin softgel capsules are formulated with a unique fixed-dose combination intended for chronic pain management. The trial will evaluate the efficacy, safety, and tolerability of these capsules in the target patient group. Calian will provide comprehensive support throughout the trial, encompassing medical writing, regulatory affairs, clinical operations, site monitoring, data management, medical monitoring, and quality assurance.

Brent Zettl, President and CEO of ZYUS, expressed his pleasure in partnering with Calian for the Phase 2 Clinical Trial. He emphasized the significance of this trial in advancing non-opioid therapies as an alternative for pain management. By working with a leading CRO, ZYUS aims to benefit from the valuable knowledge and expertise in clinical trial management.

With over two decades of experience, Calian has a track record of delivering high-quality clinical trial execution, guided by principles of teamwork, integrity, and customer commitment. The company's mission is to help people communicate, innovate, learn, stay safe, and lead healthy lives with confidence. Calian's values of customer-centricity, innovation, respect, and teamwork drive the engineering of reliable solutions to complex problems.

ZYUS Life Sciences Corporation is a Canadian-based life sciences company focused on the development and commercialization of cannabinoid-based pharmaceutical drug candidates. The company is dedicated to enhancing the understanding of cannabinoids through clinical research and intellectual property activities. ZYUS is committed to providing high-quality, cGMP/EU GMP-compliant cannabinoid products to patients and aims to elevate cannabinoids as a standard of care for pain therapeutics.

The partnership between Calian and ZYUS marks a significant step forward in the pursuit of innovative, non-opioid pain management solutions, with the potential to transform the lives of patients suffering from chronic pain.